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Steady-statedendritic cells (DCs)maintainperipheral
T cell tolerance,whereasmatureDCsgenerate immu-
nity.CD70 is acostimulatory ligandacquireduponDC
maturation. To determine its impact on T cell fate,
we have generated mice that constitutively express
CD70 in conventional DCs (cDCs). In these mice,
naive CD4+ and CD8+ T cells spontaneously convert
into effector cells. Administration of peptide without
adjuvant, which is ordinarily tolerogenic, elicited tu-
mor-eradicating CD8+ T cell responses and robust
CD4+ T cell-independent memory. CD70 was also
constitutively expressed in cDCs that inducibly pres-
ent viral epitopes. In this case, tolerance induction
was prevented as well. The antigen-presenting DCs
generated protective immunity to virus infection and
broke a pre-existing state of CD8+ T cell tolerance.
Thus, the sole expression of CD70 by otherwise im-
maturecDCssufficed toconvertCD8+Tcell tolerance
into immunity, defining the importanceofCD27-CD70
interactions at the interface between T cell and DC.
INTRODUCTION
In the absence of infection or inflammation, antigen presentation
by dendritic cells (DCs) leads to T cell tolerance and thus pre-
vents autoimmunity. Pathogens that activate Toll-like receptors
(TLRs) or other pattern-recognition receptors convert DCs from
steady state and tolerogenic to activated and immunogenic
(Steinman et al., 2003). The DC activation program includes ex-
pression of costimulatory molecules and cytokines that allow for
the generation of an adequate T cell response. Prototypical cos-
timulatory ligands on DCs are CD80 and CD86. By binding to
CD28 on the T cell, they promote cell-cycle activity and survival
of primed T cells. Other prominent costimulatory ligands belong
to the tumor necrosis factor (TNF) family (Watts, 2005). These in-
clude CD70, which is the ligand of CD27, a receptor that pro-
motes T cell survival and complements CD28 in determining
the size of effector and memory T cell populations (Hendriks934 Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc.et al., 2003; Yamada et al., 2005). Unlike other T cell costimula-
tory receptors, CD27 and CD28 are already present on naive
T cells, pointing to their importance in T cell priming.
CD70 is absent on most resting cell types, but it can be ex-
pressed on DCs, B cells, and T cells upon their activation (Borst
et al., 2005). CD70 expression is most efficiently induced on
CD8+ and CD11b+ conventional DCs (cDCs) by combined stim-
ulation of TLR and CD40 (Tesselaar et al., 2003a; Warger et al.,
2006; Sanchez et al., 2007). These conditions reflect pathogen
recognition and interaction with CD40 ligand on CD4+ T cells
and endow DCs with an optimal capacity to induce CD8+ T cell
immunity. Several lines of evidence suggest that CD70 expres-
sion is an important aspect of CD40-mediated DC ‘‘licensing,’’
i.e., giving DCs the potential to prime an effective CD8+ T cell re-
sponse (Taraban et al., 2004; Bullock and Yagita, 2005; Sanchez
et al., 2007; Schildknecht et al., 2007). We recently found that in
maturing DCs, newly synthesized CD70 traffics to late endoso-
mal compartments and is codelivered with major histocompati-
bility complex (MHC) class II to the immunological synapse
with CD4+ T cells (Keller et al., 2007). This suggests a particular
relevance of CD70 at the interface between T cell and DC.
To separate the impact of CD70 from that of other costimula-
tory molecules that are acquired by mature DCs, we have gener-
ated transgenic mice that constitutively express CD70 in DCs
under control of the CD11c promoter (Brocker et al., 1997). After
initial characterization, these mice were maintained on a Cd27-
deficient (Cd27/, also known as Tnfrsf7/) background for
prevention of pathology associated with constitutive CD27-
CD70 interactions. Using two peripheral-tolerance models, we
show that mere expression of CD70 on steady-state cDCs suf-
ficed to convert CD8+ T cell tolerance into potent antitumor and
antiviral immunity. Additionally, despite the complete absence
of CD4+ T cell help, effective CD8+ memory was generated.
These effects specifically relied on CD27-CD70 interactions at
the interface between T cell and DC because constitutive expres-
sion of CD70 on B cells did not have the same consequences.
RESULTS
Generation of CD11c-Cd70tg Mice
We generated transgenic mice, termed CD11c-Cd70tg, by using
a construct containing the full-length murine Cd70 copy DNA
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(Figure S1A available online). In mice with transgenic expression
of CD70 on B cells (CD19-Cd70tg), constitutive CD27-CD70
interactions give rise to a progressive and ultimately lethal com-
bined T cell and B cell immunodeficiency (Arens et al., 2001; Tes-
selaar et al., 2003b). We observed this pathology also in CD11c-
Cd70tg mice with onset —defined by splenomegaly—at 5 weeks
of age (data not shown). To prevent disease, we crossed these
mice onto the Cd27/ background. The first generation yielded
heterozygous CD11c-Cd70tg;Cd27+/ animals, which express
CD27 at approximately 50% of the amount expressed in wild-
type (WT) mice (Hendriks et al., 2000), allowing for interactions
with CD70. In these mice, onset of pathology was delayed until
approximately 10 weeks of age.
Figure 1. Characteristics of Transgenic
Mice Expressing CD70 under Control of
the CD11c Promoter
(A) Representative analysis of CD70 cell-surface
expression in Cd70tg;Cd27+/ mice. Splenocytes
of 6-week-old WT or Cd70tg;Cd27+/ mice were
stained with directly conjugated monoclonal anti-
body (mAb) to CD70 combined with mAb detect-
ing CD11c, CD3, or CD19 and analyzed by flow
cytometry.
(B) Phenotype of splenic T cells from CD11c-
Cd70tg mice on Cd27+/ orCd27/ backgrounds
and from WT mice of the indicated age. Cells were
stained with directly conjugated antibodies to
CD3, CD44, and CD62L. Flow-cytometric analysis
of cells within the CD3+ gate is shown. Percent-
ages of cells in the CD44loCD62L+ quadrant are
indicated.
Cd11c promoter activity has been
documented in DCs (Brocker et al.,
1997; Jung et al., 2002) but also, to a cer-
tain extent, in natural killer (NK) cells
(Laouar et al., 2005), macrophages, and
activated CD8+ T cells (Huleatt and Le-
francois, 1995; Kurts et al., 2001). Flow
cytometry of spleen cells from 6-week-
old CD11c-Cd70tg;CD27+/ mice dem-
onstrated a gain of CD70 expression in
transgenic mice as compared to WT
mice on CD11chi cells, but not on CD3+
T cells, CD19+ B cells, or CD49b+ NK
cells (Figure 1B and data not shown). Im-
munohistological examination revealed
that CD70-expressing cells were virtually
absent in spleens of WT mice, as ex-
pected (Tesselaar et al., 2003a), but
they were clearly detectable in CD11c-
Cd70tg animals (data not shown).
To investigate whether constitutive
CD27-CD70 interaction affected T cell
homeostasis, we tracked CD44 and
CD62L expression on both CD4+ and
CD8+ T cells in lymph nodes and spleens
of CD11c-Cd70tg;Cd27+/ mice. Upon
aging of these animals, both CD4+ and
CD8+ T cells spontaneously converted from a naive
CD44loCD62Lhi to an effector-memory CD44hiCD62Llo pheno-
type. This conversion was also reflected in higher expression
of the T cell effector marker CD43 (Figure 1C and Figure S1B).
In addition, mature B cell numbers in the bone marrow (BM) pro-
gressively decreased (Figure S1C). In CD11c-Cd70tg mice on
a Cd27/ background (CD11c-Cd70tg;Cd27/), no signs of
T cell activation, effector cell conversion, or B cell depletion
were observed, indicating that these processes were driven by
CD27-CD70 interactions (Figure 1C). The phenotype of CD11c-
Cd70tg mice closely parallels that of CD19-Cd70tg mice (Arens
et al., 2001; Tesselaar et al., 2003b), indicating that constitutive
expression of CD70 on DCs or B cells has similar effects on
T cell homeostasis.Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc. 935
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We performed further studies with CD11c-Cd70tg mice on the
Cd27/ background to avoid the stimulatory effects of CD27-
CD70 interactions. To examine whether CD70 transgene expres-
sion in DCs affected the development of DC subtypes, we
analyzed light-density spleen cells of CD11c-Cd70tg;Cd27/
and WT mice by flow cytometry. Lymphoid organ-resident DCs
Figure 2. Transgenic CD70 Expression on DC
Subsets
Splenocytes derived from 6-week-old WT or
Cd70tg;Cd27/ mice were enriched for DCs by density-
gradient centrifugation and stained with directly conju-
gated antibodies to CD11c, B220, and CD70 or CD11c,
CD4, CD8a, and CD70 and analyzed by flow cytometry.
(A) Gating strategy: pDCs were identified by gating on
B220+ CD11clo cells, cDCs by gating on CD11chi and
CD4+. CD8+ and CD4CD8 cDC subsets were identified
by gating within the CD11chi population.
(B) Cell-surface expression of CD70 on the indicated DC
subsets, denoted by mean fluorescence intensity (MFI).
(C) WT mice were injected i.v. with LPS alone or in combi-
nation with mAb to CD40, and 24 hr later, surface expres-
sion of CD70 on CD4+ and CD8+ cDC subsets was com-
pared with that on cDC subsets derived from naive
CD11c-Cd70tg;Cd27/ mice by flow cytometry. Data
are representative of two independent experiments.
can be divided into the type I interferon (IFN)-
producing plasmacytoid DCs (pDCs) and
cDCs that can be further subdivided into
CD8+, CD4+, and CD8CD4 cDC subsets
(Shortman and Liu, 2002). No differences were
observed in either DC subtype distribution
(Figure 2A) or DC numbers (results not shown)
between CD11c-Cd70tg and WT mice, indicat-
ing that transgene expression did not affect DC
homeostasis on a Cd27/ background.
Whereas CD70 was not found on steady-state
DCs in naive WT mice, it was expressed on all
cDC subtypes, but not on pDC, in naive
CD11c-Cd70tg;Cd27/ mice. This is in line
with the differential CD11c promoter activity in
cDCs versus pDCs (Jung et al., 2002). The
amount of CD70 expressed on steady-state
transgenic cDCs partially overlapped with that
found on TLR- and/or CD40-activated WT
cDCs (Figure 2C). We concluded that the trans-
genic mice were suitable for dissecting the
physiological effects of constitutive CD70 ex-
pression on cDCs.
CD70 Expression on Resting DCs
Induces CD8+ T Cell Expansion and
Effector Differentiation
We employed two models of peripheral toler-
ance to test whether deliberate CD70 expres-
sion on steady-state cDCs had an effect on tol-
erance induction. In the first model, we used
immunization with MHC class I-restricted oval-
bumin (OVA)257–264 peptide in PBS, which avoids DC maturation
(Diehl et al., 1999). In WT mice, this treatment induces T cell tol-
erance to a subsequent challenge with OVA peptide plus adju-
vant (Kearney et al., 1994). As responder cells, WT or Cd27/
OVA-specific OT-I T cell receptor (TCR) transgenic CD8+
T cells were used. These were injected at low numbers (1 3
104 per recipient) for approximating endogenous precursor936 Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc.
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gans (Marzo et al., 2005). OT-I T cell responses were tracked in
blood over time with OVA257–264-H-2K
b tetramers. In control
Cd27/ recipient mice, OVA-specific CD8+ T cells peaked in
number by day 6, when they constituted 7% of total CD8+
T cells (Figures 3A and 3B). This modest rise and fall in numbers
was in accordance with the described proliferation-coupled de-
letion of primed CD8+ T cells (Redmond and Sherman, 2005). In
CD11c-Cd70tg;Cd27/ recipients, however, OVA-specific
CD8+ T cells dramatically expanded to approximately 50% of to-
tal CD8+ T cells. This expansion was antigen driven, given that it
did not occur in absence of OVA peptide. It was also mediated by
CD27, given that Cd27/ OT-I T cells did not accumulate in the
same recipients (Figure 3B). Analysis of cell-surface expression
of CD40, CD80, and MHC class II on DCs in the spleen indicated
that DCs had not matured in any of the experimental groups
(Figure 3C). We conclude that the deliberate expression of
CD70 on steady-state cDCs switched an abortive response
into one of dramatic CD27-mediated clonal T cell expansion.
Under tolerogenic conditions, T cells can show some expan-
sion, as well as interleukin-2 (IL-2) production, but they generally
do not make effector cytokines such as IFNg (Hawiger et al.,
2001). At day 6 (peak of the response), IFNg-producing CD8+
T cells were hardly detectable in the spleen of control recipients,
in accordance with the tolerogenic conditions. In contrast, in
CD11c-Cd70tg recipients, approximately 25% of CD8+ T cells
produced IFNg, specifically in response to OVA peptide stimula-
tion (Figure 3D). At the same time point, the cytolytic effector po-
tential of CD8+ T cells was determined by an in vivo cytotoxicity
assay, which involves injection of CFSE-labeled, peptide-pulsed
syngeneic splenocytes (Barber et al., 2003). Strikingly, target cell
lysis was approximately 15 times greater in CD11c-Cd70tg than
in control recipients (76% versus 5%) (Figure 3E). We conclude
that the presence of CD70 on steady-state cDCs not only al-
lowed for CD27-driven expansion of CD8+ T cells, but also for
acquisition of effector functions, exemplified by production of
IFNg and cytolytic capacity.
Tumor Regression after Peptide Challenge
in CD11c-Cd70tg Mice
To be productive in an immune response, CD8+ T cells must not
only acquire effector functions, but also the capacity to migrate
from secondary lymphoid organs to the target tissue. We tested
whether OT-I T cells in CD11c-Cd70tg;Cd27/ mice chal-
lenged with peptide alone were functional in this respect by as-
sessing tumor clearance. As a first tumor model, we used a var-
iant of the poorly immunogenic B16 melanoma cell line,
engineered to express a fragment of the OVA protein (de Witte
et al., 2006). B16-OVA cells were injected subcutaneously into
CD11c-Cd70tg;Cd27/ or control Cd27/ mice 3 days before
WT or Cd27/ OT-I T cells were adoptively transferred. One
day after T cell transfer, mice were challenged with OVA pep-
tide. As observed earlier, OVA-specific CD8+ T cells expanded
substantially more in CD11c-Cd70tg;Cd27/ mice than in con-
trol mice. These enhanced T cell responses were observed in
several organs, including blood (Figure 4A), spleen, and inguinal
tumor-draining lymph nodes (Figure 4B). The responses fol-
lowed the same kinetics as after peptide challenge alone(Figure 3B), but numbers of MHC tetramer+ T cells were lower
in the blood of tumor-bearing mice. Infiltration of the tumor by
OT-I T cells was dramatically increased in CD11c-Cd70tg
mice as compared to control mice (Figure S2), indicating en-
hanced migration of effector T cells out of the circulation and
into the tissue.
Whereas tumor growth was observed in all control groups,
CD11c-Cd70tg recipients experienced complete tumor regres-
sion in concert with enhanced effector CD8+ T cell accumulation
(Figure 4C). Furthermore, tumor control in CD11c-Cd70tg mice
resulted in 100% long-term survival, whereas mice in all control
groups had to be sacrificed because of tumor outgrowth
(Figure 4C). Inclusion of the relevant controls indicated that gen-
eration of the tumor-clearing cytotoxic T lymphocyte (CTL) effec-
tor pool in CD11c-Cd70tg mice relied on CD27 expression on
OT-I T cells and the presence of OVA peptide. These data dem-
onstrate that CD8+ T cells, primed by steady-state cDCs pre-
senting OVA peptide-MHC complexes and CD70, can form fully
functional CTL effectors, capable of rejecting a model B16-OVA
tumor.
We next tested whether expression of transgenic CD70 on
immature cDCs sufficed to elicit a CD8+ T cell response to
B16 melanoma cells lacking any exogenous epitopes. B16
cells express endogenous melanocyte differentiation antigens,
such as glycoprotein 100 (gp100) and tyrosinase-related
protein 1 (TRP-1) and TRP-2, which have known MHC class
I-restricted immunodominant epitopes in C57BL/6 mice and
can be exploited to elicit antitumor immunity (Bloom et al.,
1997; Overwijk et al., 2003; Muranski et al., 2008). As for
B16-OVA, we implanted B16 cells subcutaneously into
CD11c-Cd70tg;Cd27/ and control Cd27/ mice. Because
these recipient mice are deficient in CD27, endogenous
T cells cannot interact with CD70. As for responder cells, we
adoptively transferred a polyclonal population of purified WT
(and therefore CD27-proficient) CD8+ T cells. These could be dis-
criminated from the endogenous T cells by the Ly5.1 allotype. Into
the same recipient mice, we transferred purified CD8+ T cells
from pmel-1 TCR transgenic mice that express a TCR specific
for gp10025–33 peptide in the context of H-2D
b (Overwijk et al.,
2003). One day after T cell transfer, mice were challenged with
human gp100 (hgp100), which represents an altered peptide li-
gand form of mgp100, as well as mTRP-1- and mTRP-2-derived
peptides in PBS. After the peptide vaccination, tumor growth was
monitored and T cell accumulation in blood was tracked over time
with the Ly5.1 marker and H-2Db-hgp10025–33 tetramers. The
relevant MHC tetramers for defining TCR specificities to the
mTRP-1- and mTRP-2-derived peptides were not available.
The CD8+ Ly5.1+ WT T cells expanded in response to peptide
vaccination in CD11c-Cd70tg mice, but not in control mice
(Figure 4D). This expansion was correlated with a delayed tumor
outgrowth as compared to controls (Figure 4E) and a prolonged
overall survival (Figure 4F). No expansion of the pmel-1 T cells
was observed in either recipient group (data not shown). The
Cd27/CD8+ T cells of the recipients did not expand, confirming
dependence of the T cell response on CD27-CD70 interaction
(data not shown). We conclude that deliberate expression of
CD70 on steady-state cDCs can convert peripheral CD8+ T cell tol-
erance to exogenous tumor antigens as well as endogenous tumor
antigens to tumor-specific immunity.Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc. 937
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Immunization
CD11c-Cd70tg;Cd27/ or control Cd27/ recipients received WT or Cd27/ OT-I T cells. One day after adoptive transfer, mice were challenged i.v. with OVA
peptide in PBS.938 Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc.
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B Cells, Generates Memory after Peptide Immunization
In a situation of peripheral-tolerance induction, responder T cells
are deleted or anergized and cannot respond to rechallenge,
even in the presence of optimal DC-maturation stimuli (Redmond
and Sherman, 2005). To test whether this occurred in our model,
we tested the recall response of OVA-peptide-primed OT-I
T cells by rechallenge with OVA peptide combined with lipopoly-
saccharide (LPS) and antibody to CD40. In control animals, OVA-
specific CD8+ T cells were nonresponsive to secondary chal-
lenge, demonstrating tolerance (Figures 5A and 5B). In stark
contrast, in CD11c-Cd70tg mice, OVA-specific CD8+ T cells
showed a secondary response that was faster and of greater
magnitude than the primary response and amounted to almost
70% of peripheral CD8+ T cells (Figures 5A and 5B). We con-
clude that priming of CD8+ T cells by CD70-expressing cDCs un-
der otherwise tolerizing conditions results in the formation of
potent immunological memory.
In the same experiment, we evaluated OVA-specific CD8+
T cell responses in CD19-Cd70tg mice (on a Cd27/ back-
ground) that express CD70 on B cells. In CD19-Cd70tg recipi-
ents, OVA-specific CD8+ T cells expanded somewhat more
than in control recipients, but the response was much lower
than that in CD11c-Cd70tg mice (Figures 5A and 5B) and not sig-
nificantly higher than that in control mice. Moreover, rechallenge
of CD19-Cd70tg recipients resulted in a very modest expansion
of OVA-specific CD8+ T cells, which was lower than in the pri-
mary response (Figures 5A and 5B). CD70 expression on trans-
genic B cells was much higher than on transgenic DCs and there-
fore clearly not a limiting factor (Figure 5C). This side-by-side
comparison demonstrates that prevention of tolerance specifi-
cally requires expression of CD70 on cDCs.
Antigen Presentation by Resting DCs in Cd70tg;DIETER
Mice Induces CD8+ T Cell Immunity
To directly implicate steady-state DCs in presenting antigen and
providing CD70-mediated costimulation to an endogenous rep-
ertoire of naive T cells, we used the peripheral-tolerance model
of DIETER mice. These mice express lymphocytic choriomenin-
gitis virus (LCMV)-derived CD8+ T cell epitopes on resting DCs
upon tamoxifen (TAM)-induced transgene expression. This re-
sults in induction of a well-defined state of CD8+ T cell tolerance,
which is mediated by the concerted action of CTL-associated
antigen 4 (CTLA-4) and programmed death 1 (PD-1) (Probst
et al., 2003, 2005). We crossed DIETER mice with CD11c-Cd70tg;Cd27/ mice and used BM of the F1 generation (that
was now Cd27+/) to produce chimeric mice. Eight weeks after
BM reconstitution, CD62L and CD44 on T cells were comparable
between recipients of Cd70tg;DIETER or control DIETER BM.
This indicated that Cd27+/ T cells had not yet converted into ef-
fector cells at this time point (Figure S3). In addition, cell-surface
expression of CD80, CD86, CD40, and MHC class I and II on
splenic CD11c+ cells in BM recipients were comparable to those
in naive WT mice, indicating that no DC activation had taken
place (Figure S4). Given that in this system neither T cells
nor DCs were activated, it was suitable for use in further
experiments.
To determine the impact of CD70 on CD8+ T cell tolerance
induction, we injected Cd70tg;DIETER and control DIETER chi-
meric mice with TAM, resulting in presentation of the LCMV-
derived CD8+ T cell epitopes glycoprotein (GP)33–41 and nucleo-
protein (NP)396–404 as well as bgalactosidase (Gal)497–504 by
resting CD11c+ cells in vivo. Numbers of GP- and bGal-specific
CD8+ T cells were determined 8 days later by appropriate MHC
tetramer staining of blood leukocytes. As expected (Probst
et al., 2003), naive endogenous CD8+ T cells did not expand in
TAM- or control-treated DIETER mice or in control-treated
Cd70tg;DIETER mice (Figure 6A). In contrast, endogenous
CD8+ T cells expanded in TAM-treated Cd70tg;DIETER mice
(Figure 6A). To examine whether these expanded CD8+ T cells
had acquired effector functions, we challenged the mice with
LCMV at day 8 after TAM injection and measured IFNg produc-
tion ex vivo. Resting DCs from TAM-treated Cd70tg;DIETER
mice, but not control DIETER mice, gave rise to GP33–41-specific
CD8+ T cells that produced detectable amounts of IFNg,
whereas there was no response to control peptide GP276–286
(Figure 6B). At day 5 after infection, high LCMV titers are nor-
mally found in TAM-treated DIETER mice because LCMV-spe-
cific CD8+ T cells are rendered tolerant (Probst et al., 2003). In
TAM-treated Cd70tg;DIETER mice, however, viral titers were
substantially reduced, providing further evidence for the gener-
ation of a functional CD8+ effector T cell pool (Figure 6C). Viral
clearance was not observed in control-treated Cd70tg;DIETER
mice. This confirmed that the protective CD8+ T cell response
was dependent on TAM-induced and not infection-induced
LCMV antigen presentation by CD70 transgenic DCs. Treatment
with antibody to CD40 in addition to TAM did not further en-
hance responsiveness in Cd70tg;DIETER mice (Figure 6C). We
conclude that deliberate expression of CD70 on resting, anti-
gen-presenting DCs is sufficient to convert CD8+ T cell tolerance(A) Flow-cytometric analysis of blood cells collected at days 2 and 6 after peptide challenge and stained with OVA257–264-H-2K
b tetramer and mAb to CD8.
Numbers within the plots indicate percentages of gated tetramer+ cells within the CD8+ T cell population.
(B) Percentages of tetramer+ cells among CD8+ T cells in blood. Data represent mean values (+ SEM) for five mice per group. ‘‘**’’ indicates significant difference
between WT OT-I T cell numbers in Cd70tg and control mice for p% 0.01.
(C) Flow-cytometric analysis of cell-surface expression of MHC Class II, CD40, and CD80 (MFI) on CD11c+ cells isolated at 24 or 48 hr after immunization with
OVA peptide from spleens of groups of mice indicated in (B) (nonimmunized control recipients of WT T cells were not included). The dotted line represents staining
with Ig isotype control antibody, and solid lines represent stainings for the indicated markers in different test groups.
(D) Intracellular IFNg staining of CD8+ T cells harvested from spleens at day 6 after OVA-peptide challenge and incubated in vitro for 5 hr in the presence or ab-
sence of OVA peptide. Dot plots are representative of three independent experiments. Numbers in quadrants indicate the percentages of IFNg+ cells within the
CD8+ T cell population as means (±SEM) of two mice per group.
(E) Cytotoxic activity of OVA-specific T cells in an in vivo cytotoxicity assay. OVA-peptide-pulsed or unpulsed target cells were labeled with high or low CFSE
concentration, respectively, and transferred into recipients on day 6 after OVA-peptide challenge. Histograms show the flow-cytometric analysis of CFSE+ cells
isolated from spleens 12 hr later. The numbers represent the percentage of specific killing of OVA-pulsed target cells as means (±SEM) of three mice per group.
Data are representative of three independent experiments.Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc. 939
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T cell repertoire.
Antigen Presentation by Resting CD70tg DCs Breaks
CD8+ T Cell Tolerance
We next investigated whether previously tolerized CD8+ T cells
could be reactivated by CD70-expressing steady-state DCs
(breaking of tolerance). To this end, 105 naive GP33–41-specific
P14 TCR transgenic CD8+ T cells were transferred into DIETER
mice, and TAM was given 1 day later. After 1 week, we purified
CD8+ T cells, which by that stage have been tolerized (Probst
et al., 2003), from the spleens of recipients and transferred the
equivalent of 1.5 3 103 GP33–41-specific T cells into Cd70tg;
DIETER or control DIETER mice. One day later, we injected these
secondary recipients with TAM to induce antigen presentation,
and GP33–41-specific T cell responses were evaluated 1 week
later (Figure S5). Quantification of IFNg+ GP33–41-specific
TCRtg+ CD8+ cells after short in vitro restimulation with GP33–41
peptide demonstrated that these cells were approximately
1000-fold more frequent in Cd70tg;DIETER mice than in control
DIETER mice (Figure 7). Thus, previously tolerized CD8+ T cells
could expand and gain effector function after exposure to
antigen-presenting steady-state CD70 transgenic DCs, but not
control DCs.
DISCUSSION
Induction of peripheral tolerance is mediated by steady-state
DCs and is achieved by mechanisms that are either T cell intrin-
sic (i.e., anergy, deletion) or extrinsic (i.e., T regulatory cells, cy-
tokines) (Steinman et al., 2003). Tolerizing DCs are characterized
by a low amount of MHC-peptide complexes and a lack of cos-
timulatory ligands on their surface. Upon encounter of matura-
tion stimuli, DCs undergo broad phenotypic changes that result
in upregulation of antigen-loaded MHC levels, production of im-
munostimulatory cytokines, such as IL-12, and induction of cos-
timulatory molecules, such as CD70. Using two models of pe-
ripheral tolerance, we have shown here that expression of
CD70 on otherwise tolerizing DCs allowed for CD8+ T cell differ-
entiation into effector and memory cells.
The CD27-CD70-driven acquisition of T cell effector charac-
teristics, including cytotoxic potential and capacity to migrate
and extravasate, was demonstrated by complete rejection of
B16-OVA tumors in CD11c-Cd70tg mice. The antitumor effect
of OT-I T cells required administration of the OVA peptide, in
line with deficient crosspriming by subcutaneous B16 tumors(Ochsenbein et al., 2001). CD70-mediated improvement of
antitumor immunity was previously reported (see references in
Borst et al., 2005), but this was most likely due to direct priming
by tumor cells that reached lymphoid organs. A soluble recombi-
nant form of CD70 was also shown to elicit a CD8+ T cell re-
sponse to OVA peptide in PBS, but in vivo tumor clearance
was not assessed in that study (Rowley and Al-Shamkhani,
2004). The authors transferred 100-fold higher numbers of OT-I
cells than we did in CD11c-Cd70tg mice, which disallows a direct
comparison of potency (Marzo et al., 2005).
A more stringent test for the capacity of CD70 to elicit antitu-
mor immunity was the use of the B16 tumor instead of B16-
OVA. In the case of B16, tumor antigens are derived from endog-
enous proteins, for which the T cell repertoire is centrally or
peripherally tolerized. As responder T cells, we used adoptively
transferred WT and thus CD27-proficient polyclonal CD8+
T cells, and we challenged the mice—in absence of adju-
vants—with a mixture of defined MHC class I-restricted peptides
derived from melanocyte-specific antigens expressed by B16.
The transferred CD8+ T cells expanded better and mediated bet-
ter tumor control in CD11c-Cd70tg mice than in control mice,
which translated into prolonged survival of the tumor-bearing
CD11c-Cd70tg mice. Lack of expansion of endogenous
Cd27/ T cells under the same conditions confirmed that the
CD8+ T cell response was driven by CD27-CD70 interactions.
This indicates that a strong CD27 signal delivered at the interface
between T cell and DC can trigger effector formation from T cells
that are under control of physiological central- and peripheral-
tolerance mechanisms.
As opposed to OT-I T cells, TCR transgenic pmel-1 T cells did
not expand under the same conditions in CD11c-Cd70tg hosts.
This may be explained by the documented low efficiency interac-
tion between the pmel-1 TCR and gp100-H-2Db complexes and
the concomitant weak TCR signal (Overwijk et al., 2003). The re-
cruitment of naive T cells to the responder pool most likely de-
pends on the relative strength of signaling by the TCR, CD28,
and CD27. Both TCR and CD28 signals are required for cycle en-
try, whereas CD27 delivers prosurvival signals for subsequent
T cell expansion (Hendriks et al., 2003). In CD11c-Cd70tg
mice, the modest expression of CD80 and CD86 on resting anti-
gen-presenting DCs is possibly sufficient to trigger CD28, which
supports the TCR signal to initiate cell-cycle entry. When such an
activation threshold is reached, the CD70-mediated CD27 signal
rescues these cycling cells from deletion by apoptosis. This sup-
ports the notion that some initial signaling threshold must be
met downstream from the TCR to allow CD27 to display itsFigure 4. Transgenic CD70 Expression Generates Immunity to Melanoma Tumors
(A–C) CD11c-Cd70tgCd27/ or control Cd27/ mice were injected subcutaneously with 1 3 105 B16-OVA tumor cells. Three days later, 105 WT or Cd27/
OT-I T cells were transferred, and one day later (day 0), mice were challenged with OVA peptide in PBS.
(A) Percentages of MHC tetramer+ cells among CD8+ T cells in blood. Data represent mean values (+ SEM) for five mice per group.
(B) Absolute numbers of MHC tetramer+ cells among CD8+ T cells in spleens and tumor-draining inguinal lymph nodes (DLN) at day 6 after peptide challenge.
Significant differences between WT OT-I T cell numbers in Cd70tg and control mice for **p% 0.01 in blood and spleen and for *p% 0.05 in DLN are indicated.
(C) Left: Tumor size measured by caliper. Data represent mean values (+ SEM) for four mice per group. Right: Survival data for the same groups of mice. For
symbol legend, see (A).
(D–F) CD11c-Cd70tgCd27/ or controlCd27/ mice were injected subcutaneously with 13 105 B16 tumor cells. One day later, 106 CD8+ Ly5.1+ WT T cells plus
106 pmel-1 T cells were transferred per recipient, and one day later (day 0), mice were challenged with hgp100, TRP-1, and TRP-2 peptides in PBS.
(D) Percentages of Ly5.1+ cells among total CD8+ T cells in blood.
(E) Tumor size measured by caliper. Data represent mean values (+ SEM) for four mice per group; significant differences for *p < 0.05 and **p < 0.01 are indicated.
(F) Survival data for the same groups of mice. For symbol legend, see (D).Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc. 941
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CD27-CD70 Costimulation Breaks ToleranceFigure 5. Acquisition of CD8+ T Cell Memory after Peptide Immunization in Presence of Cd70tg DCs, but Not Cd70tg B Cells
CD11c-Cd70tg;Cd27/, CD19-Cd70tg;Cd27/, or control Cd27/ recipients received WT or Cd27/ OT-I T cells. One day after adoptive transfer, mice were
challenged i.v. with OVA peptide in PBS. At day 30 after primary challenge, mice were rechallenged i.v. with a combination of LPS, mAb to CD40, and OVA peptide
in PBS.
(A) Percentages of OVA257–264-H-2K
b tetramer+ cells among CD8+ T cells in blood at the indicated days after primary and secondary OVA challenge. Data rep-
resent mean values (+ SEM) for four mice per group. Significant differences between WT OT-I T cell numbers in CD11c-Cd70tg and control mice for **p% 0.01
and *p% 0.05 are indicated. Cell numbers in CD19-Cd70tg mice did not differ significantly from those in control mice.
(B) Representative flow-cytometric analysis of blood cells collected at day 6 after rechallenge and stained with OVA257–264-H-2K
b tetramer and CD8 mAb.
Numbers within the plots indicate percentages of gated tetramer+ cells within the CD8+ T cell population.
(C) Flow-cytometric analysis of CD70 cell-surface expression (MFI) on DCs derived from CD11c-Cd70tg mice and B cells derived from CD19-Cd70tg mice, as
determined by combined staining with antibodies to CD11c or CD19 on spleen cells.antiapoptotic activity. The recruitment of T cells into the re-
sponder pool and resulting clonal expansion would then allow
for development of effector functions. Indeed, both in CD11c-
Cd70tg and CD19-Cd70tg mice expressing CD27 receptor, na-
ive CD4+ and CD8+ T cells progressively shifted to an effector
phenotype in absence of deliberate immunization. This conver-
sion to effector phenotype in CD19-Cd70tg mice is TCR driven
(Tesselaar et al., 2003b) and may result from recognition of envi-
ronmental and/or autoantigens. On a CD95-deficient back-
ground, CD19-Cd70tg mice die as early as 3 weeks of age (Arens
et al., 2005), suggesting activation of autoreactive T cells, which
are normally kept in check by CD95-mediated apoptosis. To-
gether, these observations indicate that the CD27 signal lowers942 Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc.the threshold for priming of naive T cells, which under steady-
state conditions receive a tolerizing TCR signal by (auto)antigen
recognition.
Apart from promoting survival of primed T cells, CD27 can also
impact on their effector function, as shown by increased IFNg
expression by CD4+ and CD8+ T cells in CD19-Cd70tg mice
(Arens et al., 2001) and involvement of CD70-expressing DCs
in directing a T helper 1 cell program in CD4+ T cells (Soares
et al., 2007). Possibly, development of CTL functions as ob-
served in CD11c-Cd70tg mice is driven directly by signaling
downstream from CD27. Alternatively, CD70 may signal into
DCs upon engagement by CD27 on T cells and condition the
DCs to promote CTL differentiation. In fact, signaling through
Immunity
CD27-CD70 Costimulation Breaks ToleranceCD70 on T cells and B cells was previously shown to result in
their functional changes (Arens et al., 2004a; Garcia et al., 2004).
The robust primary CD8+ T cell response to OVA peptide in
CD11c-Cd70tg recipients was followed by formation of memory
cells that were capable of secondary expansion, even though no
CD4+ T cell help was delivered at the time of priming. This in-
dicates that deliberate CD27-CD70 interaction at the T cell-DC
interface not only triggers primary effector functions, but also
allows for generation of appropriately programmed CD8+
memory T cells (Bevan, 2004) in the absence of CD4+ T cell
help. Although phenotype and behavior of T cells in CD11c-
Cd70tg mice and CD19-Cd70tg mice were to a large extent
comparable, prevention of tolerance was only observed in the
CD11c-Cd70tg mice. Physical proximity of T cells and DCs as
opposed to physical separation of T cells and B cells within the
lymph node cannot explain this because CD19-Cd70tg mice
Figure 6. Antigen Presentation by Resting Cd70tg
DCs InducesCD8+ TCell Priming and Immunity to Viral
Infection
On day 0, Cd70tg;DIETER and DIETER chimeric mice were
control treated or injected with TAM for inducing presentation
of transgenic LCMV-derived CD8+ T cell epitopes by DCs.
(A) On day 8, blood lymphocytes were stained with MHC
tetramers for detecting expansion of GP33–41- or bGal497-505-
specific CD8+ T cells (*p < 0.05, **p < 0.02).
(B) On day 8, mice were challenged with 200 pfu LCMV-WE i.v.
On day 4 after infection, acquisition of effector function of
GP33–41-specific CD8
+ T cells was determined by intracellular
IFNg staining after 5 hr in vitro incubation of splenocytes in the
presence of GP33–41 or GP276–286 control peptide (*p < 0.002).
(C) Cd70tg;DIETER chimeric mice treated on day 0 with
vehicle, TAM, or TAM plus mAb to CD40 were challenged
with 200 pfu LCMV-WE on day 8, and viral titers were deter-
mined in the spleen with a focus-forming assay on day 5 after
infection. The broken line represents the detection limit of the
assay. Data are representative of two independent experi-
ments. Symbols represent individual mice (*p < 0.02).
(Arens et al., 2001, 2004b; Tesselaar et al., 2003b)
have a dramatic phenotype. This argues that there
is enough communication between T cells and B
cells for CD27-CD70 interaction to occur. The col-
lective observations indicate that CD70 must be
available at the interface between T cell and DC
for the signals to result in the tolerance-breaking
stimulatory effects. Side-by-side comparison of
soluble recombinant CD70 and CD70 offered by
DCs should reveal to which extent functional mod-
ulation of DCs by CD70 contributes to CD8+ T cell
responsiveness.
The second model we employed allows resting
DCs to present LCMV-derived epitopes to naive,
endogenous T cells under steady-state conditions.
This results in antigen-specific tolerance, which is
dependent on signaling through PD-1 and CTLA-
4 and is not broken by challenge with a virus ex-
pressing those epitopes (Probst et al., 2003,
2005). Here, we show that mere transgenic expres-
sion of CD70 on resting DCs sufficed to induce
CD8+ T cell immunity instead of tolerance. Endogenous CD8+
T cells primed by CD70-expressing resting DCs expanded and
developed into effector CTLs that produced IFNg and protected
the host against viral infection. Moreover, we demonstrate that
LCMV-specific CD8+ T cells that had been tolerized in this sys-
tem could be recruited into an effector population upon rechal-
lenge with antigen-presenting Cd70tg DCs. These data strongly
suggest that CD27-CD70 signaling at the interface between
CD8+ T cells and DCs can overrule instructions for anergy in-
stilled by PD-1 and CTLA-4.
Our data support the concept that the balance between toler-
ance and immunity is controlled by the relative signal strength of
inhibitory and activating costimulatory molecules. Moreover,
they highlight a unique role of CD70 in decision making between
tolerance and immunity and in regulation of magnitude and qual-
ity of the immune response. This notion is supported by recentImmunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc. 943
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sion of CD70 on bystander CD4+ T cells in patients with rheuma-
toid arthritis was shown to lower the threshold for priming of au-
tologous low-avidity naive CD4+ T cells, resulting in pathology
(Lee et al., 2007). Also, in a mouse model for lupus, increased
expression of CD70 on T cells corresponded with development
of this autoimmune disease (Sawalha and Jeffries, 2007). Al-
though reversal of the tolerant state is generally unwanted, there
are instances in which it can be of benefit to the host, in partic-
ular in cancer patients. We propose that monitoring of antican-
cer vaccines, including DC-based immunotherapy, for their ca-
pacity to induce CD70 expression on cDCs may predict their
efficacy.
EXPERIMENTAL PROCEDURES
Mice
WT, Cd27/ (Hendriks et al., 2000), CD19-Cd70tg (Arens et al., 2001), and
TCR transgenic mouse strains OT-I (Hogquist et al., 1994), pmel-1 (Overwijk
et al., 2003), and P14 line 327 (Pircher et al., 1990) on a C57BL/6 background
were used for experiments at 6 to 12 weeks of age. For generation of CD11c-
Cd70tg mice (hereafter called Cd70tg), the full-length murine CD70 (mCD70)
cDNA (Tesselaar et al., 1997) was cloned into the EcoRI site of the rabbit
b-globin gene in the CD11c promoter plasmid pDOI-5 (Brocker et al., 1997)
(kindly provided by T. Brocker, Ludwig-Maximilians University, Germany).
The fragment containing the Cd11c gene promoter and Cd70 coding se-
quence was excised by digestion with NotI and SalI and microinjected into
the pronuclei of fertilized C57BL/6 oocytes. Offspring transgenic for the
CD11c-Cd70 construct were identified by PCR of genomic DNA with the
primers 50-GGATGCCGGAGGAAGGTCGCCC-30 and 50-CAAGGGCATATC
CACTGAACTC-30. Cd70tg mice were maintained as heterozygous transgenic
on aCd27/ background. Transgenic and control nontransgenic mice used in
experiments were littermates. Experiments with these mice were performed in
accordance with national guidelines and were approved by the Experimental
Animal Committee of The Netherlands Cancer Institute (DEC). DIETER mice
are double transgenic mice generated on a C57BL/6 background that express
three LCMV-derived epitopes (GP33–41, NP396–404 restricted to H-2D
b, and
GP34–41 restricted to H-2K
b) and one bGal-derived epitope (bGal497–504 re-
Figure 7. Antigen Presentation by Resting Cd70tg DCs Breaks
Tolerance
For experimental setup, see Figure S5. On day 15, splenocytes were recov-
ered from secondary recipient mice and stimulated in vitro for 5 hr in the pres-
ence of brefeldin A with or without 105 M GP33–41 peptide. Subsequently, cul-
tures were stained with antibodies directed to CD45.1, CD8, and IFNg for
enumerating the effector TCRtg cells per spleen. Symbols represent individual
mice. Incubation with medium instead of peptide induced <1% of TCRtg cells
to produce IFNg (*p < 0.004).944 Immunity 29, 934–946, December 19, 2008 ª2008 Elsevier Inc.stricted to H-2Kb) specifically in DCs upon injection of TAM (Probst et al.,
2003). Cd70tg;DIETER;Cd27+/ mice (hereafter called Cd70tg;DIETER) were
generated by crossing DIETER mice with Cd70tg;Cd27/ mice. These mice
were bred at the Institute of Laboratory Animal Science (University of Zurich,
Switzerland) and kept under specific pathogen-free conditions. Experiments
with these mice were performed in accordance with the Swiss federal and can-
tonal law on animal protection. To increase the number of available age- and
sex-matched mice carrying Cd70tg;DIETER and DIETER DCs, BM chimeras
were generated with lethally irradiated WT C57BL/6 mice as recipients for
BM isolated from Cd70tg;DIETER and DIETER littermates.
Treatment of Mice
For in vivo maturation of DCs, mice were injected i.v. with LPS from E. coli
0111:4 (Sigma) at 5 mg per mouse and sacrificed 24 hr later for analysis. For
adoptive transfer, T cells were purified from pooled spleen and lymph nodes
of naive OT-I mice to 95%–98% homogeneity with the BD IMag mouse T lym-
phocyte enrichment kit (BD Biosciences). In case of wild-type C57BL/6 Ly5.1
or pmel-1 donor mice, CD8+ T cells were purified with the BD IMag mouse CD8
T lymphocyte enrichment kit (BD Biosciences). Ly5.2 recipient mice received
104 total OT-I T cells or 106 purified CD8+ Ly5.1 plus 105 pmel-1 T cells in
Hank’s balanced salt solution (HBSS; GIBCO) i.v. (retro-orbitally) and were
challenged 1 day later with 20 mg of, respectively, OVA257–264 peptide or
hgp10025–33, TRP-1113–127, and TRP-2181–188 (synthesized with standard 9-flu-
orenylmethoxycarbonyl chemistry) in PBS i.v. For challenge with melanoma tu-
mor cell lines B16 or B16-OVA (de Witte et al., 2006), 105 cells in 200 ml HBSS
were injected subcutaneously (s.c.) on the flank. Tumors were measured with
caliper, and mice were sacrificed when tumors reached the predefined desig-
nated end point. For creation of BM chimeras, WT recipient mice were irradi-
ated with 9.5 Gy with a 57Co-source and received on the same day by i.v. in-
jection 2–33 106 BM cells from age- and sex-matched donor mice. During the
first 2 weeks after transplantation, mice were given Borgal antibiotic (Hoechst
Roussel Vet) in the drinking water. Mice were rested 8 weeks before use in ex-
periments. Cre recombinase activity was induced in BM chimeras by a single
intraperitoneal (i.p.) injection of 2 mg TAM in a volume of 0.1 ml. TAM was sus-
pended in 96% ethanol. Nine volumes of olive oil were added, and TAM was
dissolved at 37C during 1 hr. Control-treated mice were injected with
0.1 ml olive oil i.p. For inducing simultaneous DC maturation, mice were in-
jected i.v. with 50 mg of agonistic FGK45.5 antibody directed to CD40 (Rolink
et al., 1996). For virus infection, mice were injected i.v. with 200 pfu of LCMV-
WE (originally obtained from F. Lehmann-Grube at Heinrich Pette Institute,
propagated in L929 fibroblasts at a low multiplicity of infection). For protection
assays, spleens were removed 5 days after infection. Ten-fold serial dilutions
of spleen homogenates were used to infect monolayers of MC57G fibroblasts
for 48 hr. LCMV was detected with the LCMV-NP-specific antibody VL-4 as
described (Battegay et al., 1991). For adoptive transfer experiments, naive
CD8+ T cells were purified from P14 TCRtg mice of the CD45.1 allotype by
MACS according to the manufacturer’s instructions, and 105 specific T cells
were transferred into DIETER mice at day 1. DIETER mice were injected
with 2 mg TAM at day 0 for inducing tolerance of P14 TCRtg cells. At day 7,
CD8+ T cells were isolated from DIETER mice, and an equivalent of 1500
TCRtg CD8+ T cells (as measured by CD8, Va2, and CD45.1 triple staining)
were transferred into Cd70tg;DIETER and into DIETER mice. At day 8, antigen
presentation in Cd70tg;DIETER and DIETER mice by steady-state DCs was in-
duced by the injection of 2 mg TAM. At day 15, the IFNg-producing TCRtg cells
were enumerated in the spleen.
In Vivo Cytotoxicity Assay
The in vivo cytotoxicity assay was performed as described (Barber et al.,
2003). Briefly, splenocytes from naive mice labeled with CFSE (Invitrogen)
were used as targets. Cells labeled with 5 mM CFSE were pulsed with 10 mg/ml
OVA257–264 peptide, and cells labeled with 0.5 mM CFSE were left unpulsed.
Target cells were transferred i.v. (5 3 106 cells of each population) into indi-
cated recipients, and 16 hr later, their spleens were analyzed by flow cytome-
try. Percent killing was calculated as follows: 100  ([(% peptide-pulsed
targets in peptide-vaccinated recipients/% unpulsed targets in peptide-vacci-
nated recipients)/(% peptide-pulsed targets in untreated recipients/% un-
pulsed targets in untreated recipients)] 3 100).
Immunity
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Blood samples were collected from the tail vain into PBS containing 50 IU/ml
heparin (Leo Pharma BV). Spleen and inguinal tumor-draining lymph nodes
were passed through 70 mm single-cell strainer (BD Falcon). BM was flushed
from tibiae and femurs with a G21 needle. Erythrocytes were lysed on ice for
1 min in 0.14 M NH4Cl, 0.017 M Tris-HCl [pH 7.2]. DCs were enriched from
spleen cell suspensions by density-gradient separation as described (Naik
et al., 2003). Briefly, spleens were digested for 20 min at room temperature
with collagenase type 3 (Worthington) and DNAase I (Roche) and next incu-
bated with EDTA. All subsequent procedures were performed at 0C to 4C
for prevention of DC maturation. Light-density cells were selected by centrifu-
gation in a medium containing Nycoprep 1.077 (Axis-Shield) and incubated
with specific antibodies conjugated to FITC, PE, or allophycocyanin (APC).
Flow Cytometry
Tetrameric complexes of biotinylated murine MHC class I H-2Db or H-2Kb
heavy chain, b2 microglobulin, and relevant peptide were prepared as de-
scribed (Altman et al., 1996), labeled with PE- or APC-conjugated streptavidin,
and used in combination with CD8a mAb 53-6.7 (BD Biosciences) or CD8a
mAb CT-CD8a (Invitrogen, Caltag). Incubations were performed in staining
buffer (PBS, 1% BSA, 0.01% sodium azide). mAbs used included anti-CD33
(145-2C11), anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-CD8b (53-5.8), anti-
CD11c (HL3), anti-CD19 (1D3), anti-CD40 (3/23), anti-CD43 (1B11), anti-
CD44 (IM7), anti-CD45.1 (A20), anti-CD45R (RA3-6B2), anti-CD62L (MEL-
14), anti-CD70 (FR70), anti-CD80 (16-10A1), anti-IgD (11-26c.2a), anti-IgM
(II/41), anti-IFNg (XMG1.2), anti-MHC Class II I-Ab (AF6-120.1), and anti-TCR
Va2 (B20.1). These antibodies were obtained from BD Biosciences, eBio-
science, or prepared as purified Ig from available hybridomas. Cells were an-
alyzed by flow cytometry with FACSCalibur (Becton Dickinson) and FlowJo
Analysis Software (Tree Start). Propidium iodide-stained dead cells were ex-
cluded from analysis. For intracellular staining to detect IFNg, cells were incu-
bated for 6 hr at 37C with 106 M peptide (OVA257–264 [SIINFEKL], GP33–41
[KAVYNFATC], or GP276–286 [SGVENPGGYCL], which were synthesized by
NeoMPS in immunograde quality) or with medium alone, in the presence of
5 mg/ml Brefeldin A. Cells were surface stained with CD8a mAb, fixed and per-
meabilized with BD Cytofix/Cytoperm solution (BD Biosciences) according to
manufacturer’s protocol, and stained intracellularly with IFNg mAb.
Immunohistochemistry
Tumors were frozen in Tissue Tek (Sekura Finetek) at 70C, and 5 mm cryo-
stat sections were prepared on SuperFrostPlus (Menzel-Gla¨zer) microscope
glass slides. Sections were dried overnight, fixed in acetone for 10 min, air
dried, and rehydrated in presence of FcBlock (BD) for 60 min at room temper-
ature. Sections were incubated overnight at 4C with biotinylated rat anti-
mouse CD8bmAb, washed three times with PBS, and subsequently incubated
for 60 min at room temperature with Alexa 568-conjugated streptavidin (Mo-
lecular Probes). Sections were washed with PBS, mounted in Vectashield
(Vector Laboratories), and viewed under a Leica TCS NT confocal laser-
scanning microscope (Leica Microsystems).
Statistics
Statistical significance was determined with the two-tailed Student’s t test.
Figure legends indicate statistics on data shown.
SUPPLEMENTAL DATA
Supplemental Data include five figures and can be found with this article online
at http://www.immunity.com/supplemental/S1074-7613(08)00499-8.
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